Core Insights - The increasing prevalence of gout and hyperuricemia in China presents a significant market opportunity for innovative treatments, with approximately 221 million hyperuricemia patients and 25.3 million gout patients projected for 2024 [2][13]. - New Element Pharmaceuticals, a company focused on gout treatment, is seeking to go public in Hong Kong, facing competition from established firms like Hengrui Medicine and Kanyuan Pharmaceutical [3][16]. Company Overview - New Element Pharmaceuticals was founded in 2012 and has undergone five rounds of financing, raising approximately 1.078 billion RMB, with a current valuation of about 3 billion RMB [4][6]. - The company is led by Dr. Shi Dongfang, who has extensive experience in drug development and holds a significant stake in the company [8][4]. Product Pipeline - The company is developing two clinical-stage products, ABP-671 and ABP-745, targeting gout and hyperuricemia, along with several preclinical candidates [16][26]. - ABP-671 is a URAT1 inhibitor currently in phase 2b/3 clinical trials in the US and China, showing promise as a first-line treatment for gout [18][20]. Financial Performance - New Element Pharmaceuticals has reported significant losses over the past two and a half years, totaling 696 million RMB, with no products approved for commercial sale yet [29][31]. - The company's R&D expenses have been substantial, accounting for over 90% of total operating expenses, indicating a strong focus on developing its drug pipeline [32][33]. Market Landscape - The global market for hyperuricemia and gout treatments is estimated at approximately 3.2 billion USD, with a growing need for safer and more effective therapies [12][20]. - The competitive landscape includes multiple established pharmaceutical companies and over 100 generic drugs approved for treating hyperuricemia and gout, highlighting the challenges New Element Pharmaceuticals faces [20][22][23].

利伯特与将于2025年9月30日退任集团主席及董事会成员职务的杜嘉祺，近数月来按照监管规定进行彻 底交接程序，确保职责平稳过渡。 根据公司于2025年6月6日发表的公告，公司确认利伯特将按照股东于2025年股东周年大会上批准的董事 薪酬政策，收取每年150万英镑酬金。在担任临时集团主席期间，利伯特将不会就其于公司及其附属公 司HSBC UK Bank plc董事会的其他职务收取额外董事酬金。 格隆汇9月26日丨汇丰控股(00005.HK)今日确认，利伯特将自2025年10月1日起担任临时集团主席职务。 ...

格隆汇9月26日丨华润建材科技(01313.HK)发布公告，自2025年9月26日起，李保军获委任为执行董事。 ...

格隆汇9月26日丨浙江交科(002061.SZ)公布，公司于2025年9月25日收到浙江交通集团出具的《关于增 持股份触及1%整数倍的告知函》，浙江交通集团于2025年6月19日至2025年9月25日期间通过深圳证券 交易所以集中竞价方式累计增持公司股份26,705,483.00股，占公司总股本1.00%。本次增持后，浙江交 通集团持有公司股份1,148,337,109股，占公司总股本的43.00%，变动触及1%的整数倍。本次增持计划 尚未实施完毕，浙江交通集团将继续实施增持计划。 ...

至于对CDMO企业来说，该行预期美国本土生产成本的增加将由跨国药企客户承担，而药明生物已布局 美国产能，目前在美国新泽西州已拥有4000升产能，并计划于2027年前新增3.6万升产能，相较之下三 星生物制药尚未在美设厂，建议投资者可趁股价调整时吸纳药明生物。 杰富瑞发表研究报告指，美国总统特朗普在提出200%药品关税威胁两个月后，再宣布对品牌药或专利 药征收100%关税，以推动制造业本土化。由于中国药企对美国市场的直接药品销售极少，加上中国生 物科技公司可透过与跨国药企的合作模式，免于关税影响，因此该行相信影响有限。 ...

9月26日，港股三大指数集体收跌，恒生科技指数跌2.89%报6195点，恒生指数跌1.35%再度回到26000 关口附近，国企指数跌1.49%险守9300点。 | 代码 | 名称 √ | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 800000 | 恒生指数 | 0 | 26128.20 | -356.48 | -1.35% | | 800700 | 恒生科技指数 | | 6195.11 | -184.08 | -2.89% | | 800100 | 国企指数 | | 9303.10 | -141.12 | -1.49% | 盘面上，重科技股集体下挫，小米大跌超8%，京东、快手、阿里巴巴跌超3%；机器人概念股集体下 跌，地平线机器人跌超8%；特朗普表示10月1日起对任何品牌或专利的医药产品征收100%的关税，生 物医药股集体下跌，创新药方向跌幅明显；美国考虑限制海外芯片进口，半导体芯片股多数出现下跌行 情，龙头中芯国际跌5%。另一方面，2025年1-7月中国风力发电量产量累计增长10.4%，风电股全天表 现强势，金风科技涨超4%；重型 ...

Group 1 - The company is currently focused on distribution activities for surgical robot products and does not engage in research and manufacturing [1] - There are no recorded research and development expenses related to medical brain-machine interfaces and humanoid robots [1] - The existing research funding is primarily invested in the digitalization of medical device distribution, including business systems, data platforms, and SPD information systems [1]

进一步宣布，李忠成辞任后，吴东澄已获委任为联席公司秘书、授权代表及法律程序代理人，自2025年 9月26日起生效。李玲梅将继续担任另一名联席公司秘书。 格隆汇9月26日丨泰德医药(03880.HK)此宣布，李忠成已提出辞任(i)公司联席公司秘书；(ii)联交所证券 上市规则第3.05条项下的授权代表("授权代表")；及(iii)根据上市规则第19A.13(2)条及香港法例第622章 公司条例第16部所规定代表公司于香港接收法律程序文件及通知之代表("法律程序代理人")，自2025年9 月26日起生效。 ...

格隆汇9月26日丨富智康集团(02038.HK)发布公告，2025年9月26日耗资175.36万港元回购10.2万股，回 购价格每股17.12-17.34港元。 ...

Group 1 - The company is currently focused on distribution activities for surgical robot products and does not engage in research and manufacturing [1] - There are no recorded research and development expenses related to medical brain-machine interfaces and humanoid robots [1] - The existing research funding is primarily invested in the digitalization of medical device distribution, including business systems, data platforms, and SPD information systems [1]